USA Question and Answer

Q&A with Dan Rubinfeld

Q&A with Dan Rubinfeld

GCR USA - 21 July 2017

Economist Daniel Rubinfeld is a senior consultant at Compass Lexecon, a former deputy assistant attorney general at the Department of Justice's antitrust division - where he helped to make the case against Microsoft - and a professor of law and economics at the University of California at Berkeley. GCR USA met with Rubinfeld on the sidelines of an airline competition conference to discuss his doubts regarding the European Commission's dominance cases against Google.

Q&A with Layne Kruse

Q&A with Layne Kruse

GCR USA - 30 May 2017

Norton Rose Fulbright partner Layne Kruse will moderate a panel on antitrust litigation and compliance programmes at GCR Live Antitrust Litigation in New York next month. He talked to GCR USA about his personal experience with compliance programmes; what he hopes people will take away from the panel; and some big companies that have been punished by having a compliance programme imposed on them.

Q&A with Ronan Harty

Q&A with Ronan Harty

GCR USA - 22 May 2017

Davis Polk & Wardwell partner Ronan Harty will co-chair GCR Live Antitrust Litigation in New York next month. He talked to GCR USA about what to expect at the conference, the impact of the Trump administration on antitrust and his experience representing US and non-US companies.

Q&A with Marguerite Sullivan

Q&A with Marguerite Sullivan

GCR USA - 15 May 2017

Latham & Watkins partner Marguerite Sullivan will moderate a panel on the coordination of global litigation at GCR Live Antitrust Litigation in New York next month. She talks to GCR about the differences between antitrust culture between the US and EU, managing multi-jurisdictional matters, and the hardest case she’s faced so far.

Q&A with Daniel Crane

Q&A with Daniel Crane

GCR USA - 11 May 2017

University of Michigan law professor and Paul Weiss Rifkind Wharton & Garrison litigation counsel Daniel Crane will present “Antitrust Litigation: The year in review” at GCR Live Antitrust Litigation in New York next month. Ahead of the conference, Crane spoke about what drew him into antitrust, the trends he sees among practitioners, and the role of antitrust in policing both government and driverless cars.

An interview with Deborah Feinstein

An interview with Deborah Feinstein

GCR USA - 08 May 2017

Deborah Feinstein, the former director of the Federal Trade Commission’s bureau of competition, spoke to Charles McConnell in late April about her time at the commission, and shared thoughts about congressional legislation, divestitures in retail mergers, cooperation with the Department of Justice’s antitrust division and more.

Q&A with Bruce Simon

Q&A with Bruce Simon

GCR USA - 24 March 2017

Pearson Simon & Warshaw partner Bruce Simon will moderate the panel “To the ends of the earth? Extraterritorial application of cartel laws today” at next week’s second annual GCR Live Cartels.

Q&A with Deborah Garza

Q&A with Deborah Garza

GCR USA - 23 March 2017

Covington & Burling partner Deborah Garza, a former head of the Department of Justice's antitrust division, is set to moderate a roundtable of former DOJ officials at next week’s second annual GCR Live Cartels.

Q&A with Megan Dixon

Q&A with Megan Dixon

GCR USA - 22 March 2017

Megan Dixon is a partner at Hogan Lovells in San Francisco. She will moderate the panel “Navigating muddy waters: Steering global businesses through fluid and disparate standards” at next week’s second annual GCR Live Cartels.

Q&A with Paul Weiss's Andrew Forman

Q&A with Paul Weiss's Andrew Forman

GCR USA - 06 March 2017

Andrew Forman, a partner at Paul Weiss Rifkind Wharton & Garrison, has been part of the team at the centre of the Anthem/Cigna merger fight, but it is just the latest healthcare matter on his resume. While his headline-grabbing representations in private practice range from the US Airways/American Airlines tie-up to Eli Lilly's acquisition of Novartis Animal Health, as an attorney in the Mergers I shop of the Federal Trade Commission’s Bureau of Competition, he scrutinised deals in the pharmaceutical and medical device sectors, as well as others.